Home/EnClear Therapies/Kevin Kalish

KK

Kevin Kalish

COO

EnClear Therapies

Therapeutic Areas

Neuro-oncology Neurodegenerative Diseases Lysosomal Storage Diseases Autoimmune Diseases

EnClear Therapies Pipeline

Drug	Indication	Phase
EnTrega Platform for Leptomeningeal Carcinomatosis	Leptomeningeal Carcinomatosis (LC)	Pre-clinical

Leadership Team at EnClear Therapies

President & CEO

Marcie Glicksman

William Gormley

View full EnClear Therapies profile